title: Metabolic control of excessive extracellular nucleotide accumulation by CD39/ecto-nucleotidase-1: implications for ischemic vascular diseases.
abstract: Platelets are responsible for maintaining vascular integrity. In thrombocytopenic states, vascular permeability and fragility increase, presumably due to the absence of this platelet function. Chemical or physical injury to a blood vessel induces platelet activation and platelet recruitment. This is beneficial for the arrest of bleeding (hemostasis), but when an atherosclerotic plaque is ulcerated or fissured, it becomes an agonist for vascular occlusion (thrombosis). Experiments in the late 1980s cumulatively indicated that endothelial cell CD39-an ecto-ADPase-reduced platelet reactivity to most agonists, even in the absence of prostacyclin or nitric oxide. As discussed herein, CD39 rapidly and preferentially metabolizes ATP and ADP released from activated platelets to AMP, thereby drastically reducing or even abolishing platelet aggregation and recruitment. Since ADP is the final common agonist for platelet recruitment and thrombus formation, this finding highlights the significance of CD39. A recombinant, soluble form of human CD39, solCD39, has enzymatic and biological properties identical to the full-length form of the molecule and strongly inhibits human platelet aggregation induced by ADP, collagen, arachidonate, or TRAP (thrombin receptor agonist peptide). In sympathetic nerve endings isolated from guinea pig hearts, where neuronal ATP enhances norepinephrine exocytosis, solCD39 markedly attenuated norepinephrine release. This suggests that NTPDase (nucleoside triphosphate diphosphohydrolase) could exert a cardioprotective action by reducing ATP-mediated norepinephrine release, thereby offering a novel therapeutic approach to myocardial ischemia and its consequences. In a murine model of stroke, driven by excessive platelet recruitment, solCD39 reduced the sequelae of stroke, without an increase in intracerebral hemorrhage. CD39 null mice, generated by deletion of apyrase-conserved regions 2 to 4, exhibited a decrease in postischemic perfusion and an increase in cerebral infarct volume when compared with controls. "Reconstitution" of CD39 null mice with solCD39 reversed these changes. We hypothesize that solCD39 has potential as a novel therapeutic agent for thrombotic diatheses.
authors.affiliation: Department of Medicine, Department of Medicine, College of Physicians and Surgeons, Columbia University, New York, New York 10010, USA. ajmarcus@med.cornell.edu
authors.forename: Aaron J
authors.initials: AJ
authors.lastname: Marcus
authors.forename: M Johan
authors.initials: MJ
authors.lastname: Broekman
authors.forename: Joan H F
authors.initials: JH
authors.lastname: Drosopoulos
authors.forename: Naziba
authors.initials: N
authors.lastname: Islam
authors.forename: David J
authors.initials: DJ
authors.lastname: Pinsky
authors.forename: Casilde
authors.initials: C
authors.lastname: Sesti
authors.forename: Roberto
authors.initials: R
authors.lastname: Levi
mesh_terms: D000818:Animals; D015703:Antigens, CD; D001081:Apyrase / Q000235:genetics / Q000378:metabolism*; D002545:Brain Ischemia / Q000201:enzymology / Q000378:metabolism*; D002450:Cell Communication; D004730:Endothelium, Vascular / Q000502:physiology; D006487:Hemostasis / Q000502:physiology; D006801:Humans; D016297:Mutagenesis, Site-Directed; D009711:Nucleotides / Q000378:metabolism*; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology; D013564:Sympathetic Nervous System / Q000201:enzymology; D013927:Thrombosis / Q000473:pathology; D014652:Vascular Diseases / Q000201:enzymology / Q000378:metabolism*
chemical_list: D015703:Antigens, CD; D009711:Nucleotides; D010975:Platelet Aggregation Inhibitors; D001081:Apyrase; C067869:CD39 antigen